Arista for ALT Donor Sites to Reduce Drain Output

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Seroma
Interventions
DEVICE

ARISTA

According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components

Trial Locations (1)

94115

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Davol Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT02477774 - Arista for ALT Donor Sites to Reduce Drain Output | Biotech Hunter | Biotech Hunter